FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366332489> ?p ?o ?g. }

• W4366332489 endingPage "658" @default.
• W4366332489 startingPage "640" @default.
• W4366332489 abstract "Specific targets for cancer treatment are highly desirable, but still remain to be discovered. While previous reports suggested that CAPRIN-1 localizes in the cytoplasm, here we now show that part of this molecule is strongly expressed on the cell membrane surface in most solid cancers, but not normal tissues. Notably, the membrane expression of CAPRIN-1 extended to the subset of highly tumorigenic cancer stem cells and epithelial-mesenchymal transition (EMT)-induced metastatic cancer cells. In addition, we revealed that cancer cells with particularly high CAPRIN-1 surface expression exhibited enhanced tumorigenicity. We generated a therapeutic humanized anti-CAPRIN-1 antibody (TRK-950), which strongly and specifically binds to various cancer cells and shows antitumor effects via engagement of immune cells. TRK-950 was further developed as a new cancer drug and a series of preclinical studies demonstrates its therapeutic potency in tumor-bearing mouse models and safety in a relevant cynomolgus monkey model. Together, our data demonstrate that CAPRIN-1 is a novel and universal target for cancer therapies. A phase I clinical study of TRK-950 has been completed (NCT02990481) and a phase Ib study (combination with approved drugs) is currently underway (NCT03872947) in the United States and France. In parallel, a phase I study in Japan is in progress as well (NCT05423262).Antibody-based cancer therapies have been demonstrated to be effective, but are only approved for a limited number of targets, because the majority of these markers is shared with healthy tissue, which may result in adverse effects. Here, we have successfully identified CAPRIN-1 as a novel truly cancer-specific target, universally expressed on membranes of various cancer cells including cancer stem cells. Clinical studies are underway for the anti-CAPRIN-1 therapeutic antibody TRK-950." @default.
• W4366332489 created "2023-04-20" @default.
• W4366332489 creator A5005434602 @default.
• W4366332489 creator A5006316606 @default.
• W4366332489 creator A5009766303 @default.
• W4366332489 creator A5014427933 @default.
• W4366332489 creator A5014512466 @default.
• W4366332489 creator A5019240223 @default.
• W4366332489 creator A5034727945 @default.
• W4366332489 creator A5038445578 @default.
• W4366332489 creator A5050983837 @default.
• W4366332489 creator A5056482592 @default.
• W4366332489 creator A5058816620 @default.
• W4366332489 creator A5062148863 @default.
• W4366332489 creator A5066418231 @default.
• W4366332489 creator A5069947645 @default.
• W4366332489 date "2023-04-18" @default.
• W4366332489 modified "2023-10-04" @default.
• W4366332489 title "Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950" @default.
• W4366332489 cites W1543610375 @default.
• W4366332489 cites W1830277452 @default.
• W4366332489 cites W1940858135 @default.
• W4366332489 cites W1971095929 @default.
• W4366332489 cites W1984201622 @default.
• W4366332489 cites W1999501439 @default.
• W4366332489 cites W2007749743 @default.
• W4366332489 cites W2012613971 @default.
• W4366332489 cites W2016946888 @default.
• W4366332489 cites W2027795416 @default.
• W4366332489 cites W2036877886 @default.
• W4366332489 cites W2043228552 @default.
• W4366332489 cites W2045602001 @default.
• W4366332489 cites W2056038424 @default.
• W4366332489 cites W2065941404 @default.
• W4366332489 cites W2112018838 @default.
• W4366332489 cites W2128070247 @default.
• W4366332489 cites W2131170195 @default.
• W4366332489 cites W2139440265 @default.
• W4366332489 cites W2161267894 @default.
• W4366332489 cites W2169825756 @default.
• W4366332489 cites W2204695292 @default.
• W4366332489 cites W2394809049 @default.
• W4366332489 cites W2516365506 @default.
• W4366332489 cites W2524451426 @default.
• W4366332489 cites W2588432900 @default.
• W4366332489 cites W2623709996 @default.
• W4366332489 cites W2736218798 @default.
• W4366332489 cites W2763367287 @default.
• W4366332489 cites W2771032809 @default.
• W4366332489 cites W2783337717 @default.
• W4366332489 cites W2895926103 @default.
• W4366332489 cites W2905574941 @default.
• W4366332489 cites W2942633896 @default.
• W4366332489 cites W2970782214 @default.
• W4366332489 cites W2989969610 @default.
• W4366332489 cites W2991163352 @default.
• W4366332489 cites W3010217167 @default.
• W4366332489 cites W3035186120 @default.
• W4366332489 doi "https://doi.org/10.1158/2767-9764.crc-22-0310" @default.
• W4366332489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37082579" @default.
• W4366332489 hasPublicationYear "2023" @default.
• W4366332489 type Work @default.
• W4366332489 citedByCount "0" @default.
• W4366332489 crossrefType "journal-article" @default.
• W4366332489 hasAuthorship W4366332489A5005434602 @default.
• W4366332489 hasAuthorship W4366332489A5006316606 @default.
• W4366332489 hasAuthorship W4366332489A5009766303 @default.
• W4366332489 hasAuthorship W4366332489A5014427933 @default.
• W4366332489 hasAuthorship W4366332489A5014512466 @default.
• W4366332489 hasAuthorship W4366332489A5019240223 @default.
• W4366332489 hasAuthorship W4366332489A5034727945 @default.
• W4366332489 hasAuthorship W4366332489A5038445578 @default.
• W4366332489 hasAuthorship W4366332489A5050983837 @default.
• W4366332489 hasAuthorship W4366332489A5056482592 @default.
• W4366332489 hasAuthorship W4366332489A5058816620 @default.
• W4366332489 hasAuthorship W4366332489A5062148863 @default.
• W4366332489 hasAuthorship W4366332489A5066418231 @default.
• W4366332489 hasAuthorship W4366332489A5069947645 @default.
• W4366332489 hasBestOaLocation W43663324891 @default.
• W4366332489 hasConcept C121608353 @default.
• W4366332489 hasConcept C126322002 @default.
• W4366332489 hasConcept C159654299 @default.
• W4366332489 hasConcept C203014093 @default.
• W4366332489 hasConcept C502942594 @default.
• W4366332489 hasConcept C71924100 @default.
• W4366332489 hasConcept C96232424 @default.
• W4366332489 hasConceptScore W4366332489C121608353 @default.
• W4366332489 hasConceptScore W4366332489C126322002 @default.
• W4366332489 hasConceptScore W4366332489C159654299 @default.
• W4366332489 hasConceptScore W4366332489C203014093 @default.
• W4366332489 hasConceptScore W4366332489C502942594 @default.
• W4366332489 hasConceptScore W4366332489C71924100 @default.
• W4366332489 hasConceptScore W4366332489C96232424 @default.
• W4366332489 hasFunder F4320324230 @default.
• W4366332489 hasIssue "4" @default.
• W4366332489 hasLocation W43663324891 @default.
• W4366332489 hasLocation W436633248910 @default.
• W4366332489 hasLocation W436633248911 @default.

• next